Last updated on August 2019

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome


Brief description of study

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

Clinical Study Identifier: NCT03473223

Find a site near you

Start Over

8400661 - Norton Cardiovascular Associates

Louisville, KY United States
2.38miles
  Connect »

8400880 - Jewish Hospital - Louisville

Louisville, KY United States
5.74miles
  Connect »